AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

EYPT · NASDAQ · Biotechnology

EyePoint (EYPT)

Develops sustained-release retinal therapies built around DURAVYU and Durasert E technology.

$4.14

After hours+0.07 (+1.68%)

At close$4.07(+1.24%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	15	14	12	9	11	12	24	5	1	1	1	1
Cost of revenue	1	1	1	1	1	1	1	0	1	0	1	0
Gross profit	14	13	11	8	10	11	24	5	0	0	0	1
	28	29	44	43	43	56	72	67	62	71	87	98
Research & development	17	18	30	30	30	43	59	55	48	59	72	84
	11	11	14	13	13	13	14	12	15	11	15	14
Selling & marketing	0	0	0	0	0	0	0	0	0	0	0	0
General & administrative	11	11	14	13	13	13	14	12	14	11	15	14
Operating income	−14	−16	−33	−35	−33	−45	−49	−62	−62	−70	−87	−97
	2	2	4	4	3	4	4	3	2	3	2	3
Interest income	2	2	4	4	3	4	4	3	2	3	2	3
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−2	−2	−4	−4	−3	−4	−4	−3	−2	−12	−2	−3
Income before tax	−13	−14	−29	−31	−29	−41	−45	−59	−60	−67	−85	−94
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−13	−14	−29	−31	−29	−41	−45	−59	−60	−67	−85	−94
Other adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Net income	−13	−14	−29	−31	−29	−41	−45	−59	−60	−68	−85	−94
EPS, basic	−$0.33	−$0.33	−$0.55	−$0.58	−$0.54	−$0.64	−$0.65	−$0.85	−$0.85	−$0.81	−$0.99	−$1.09
EPS, diluted	−$0.33	−$0.33	−$0.55	−$0.58	−$0.54	−$0.64	−$0.65	−$0.85	−$0.85	−$0.81	−$0.99	−$1.09
Weighted average shares, basic	38	42	53	53	54	65	70	70	70	83	86	87
Weighted average shares, diluted	38	42	53	53	54	65	70	70	70	83	86	87
EBITDA	−12	−14	−29	−30	−29	−41	−45	−59	−59	−58	−84	−93
Depreciation & amortization	0	0	0	0	0	0	0	1	1	1	1	1
EBIT	−13	−14	−29	−31	−29	−41	−45	−59	−60	−59	−85	−94